Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

B-cell maturation antigen targeted CD3-engaging bispecific molecule for...

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

$B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )$

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA...

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

$Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )$

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma...

Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients ( Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic )

Idecabtagene vicleucel for relapsed and refractory multiple myeloma

Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA

$Idecabtagene vicleucel for relapsed and refractory multiple myeloma ( Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA )$

Myelodysplastic syndromes (MDS)

Dr Fernando Vargas - Memorial Healthcare System, FL, USA

Myelodysplastic syndromes (MDS) ( Dr Fernando Vargas - Memorial Healthcare System, FL, USA )

Updates in Hodgkin’s and non-Hodgkin lymphomas

Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA

Updates in Hodgkin’s and non-Hodgkin lymphomas ( Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA )

More from ecancer